Introduction: The full impact of COVID-19 infections on patients with cancer who are actively being treated with chemotherapy or immune checkpoint inhibitors (ICIs) has not been fully defined. Our goal was to track clinical outcomes in this specific patient population. Methods: We performed a retrospective chart review of 121 patients (age > 18 years) at the University of Alabama at Birmingham…
Learn about Progressive Supranuclear Palsy, including symptoms, causes, and treatments. If you or a loved one is affected by this condition, visit NORD to
The workplace is often presented as a meritocracy, where you can succeed by putting your head down and working hard. Wall Street veteran Carla Harris…
The negative impact and management of disruptive behavior are discussed in the article by Monika Kumar, et al.
With practice-changing data and new approaches, it was a big year in lung cancer. Devika Das, MD, and Charu Aggarwal, MD, MPH, discuss 2023’s key…
Anil (Monty) Kapoor died on Feb. 28 after being prescribed a cancer drug that was toxic to him. From left, brothers Dr. Vimal (Scott) Kapoor,…
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
The American Lung Association’s LUNG FORCE “State of Lung Cancer” report shows how the toll of lung cancer varies by state. Look at the rates…
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
